



# Identification of a CE-SDS shoulder peak as disulfide- linked fragments from common CH2 cleavages in IgGs and IgG-like bispecific antibodies

Conner Parthemore MS

# Publication

MABS  
2021, VOL. 13, NO. 1, e1981806 (14 pages)  
<https://doi.org/10.1080/19420862.2021.1981806>



REPORT

OPEN ACCESS



## Identification of a CE-SDS shoulder peak as disulfide-linked fragments from common C<sub>H</sub>2 cleavages in IgGs and IgG-like bispecific antibodies

Mingyan Cao <sup>a</sup>, Yang Jiao<sup>a</sup>, Conner Parthemore<sup>a</sup>, Samuel Korman<sup>a</sup>, Jiao Ma<sup>a</sup>, Alan Hunter<sup>b</sup>, Greg Kilby<sup>a</sup>, and Xiaoyu Chen<sup>a</sup>

<sup>a</sup>Analytical Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; <sup>b</sup>Purification Process Sciences, Biopharmaceutical Development, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA




# Introduction


- Therapeutic protein fragmentation is a critical quality attribute
- SEC is traditionally used to monitor aggregates, while CE-SDS is used to monitor fragments
- IgG1 HC CDR fragments typically appear as shoulder peaks in CE-SDS
- RPLC, intact mass, and top-down MS2 provide fundamental intrachain cysteine bonds in antibody folding domains, including the C<sub>H</sub>2 domain and possible intrachain disulfide bond clippings
- In our study, we identify a non-reduced CE-SDS shoulder peak appearing in a bispecific antibody (bsAb-A) after heat stress
- Our study suggests that host cell proteases are the cause of C<sub>H</sub>2 clipping in both mAb and bsAbs




**Figure 1.** Comparison of non-reduced and reduced CE-SDS profiles and degradation rates of three bsAb-A drug substance lots under accelerated stress conditions at 40°C up to three months. (A) nrCE-SDS overlay of heat-stressed Lot A, Lot B and Lot C; (B) rCE-SDS overlay of heat-stressed Lot A, Lot B and Lot C; (C) % purity of Lot A, Lot B and Lot C by nrCE-SDS; (D) % purity of Lot A, Lot B and Lot C by rCE-SDS









**Figure 2** nrCE-SDS profiles of HIC fractions from 40°C 1 mon heat-stressed bsAb-A, in which size variant peaks are labeled from 1 to 11 (A) nrCE-SDS profiles of HIC prepeaks and main peak; (B) nrCE-SDS profiles of HIC post peaks.

















**Figure 2** nrCE-SDS profiles of HIC fractions from 40°C 1 mon heat-stressed bsAb-A, in which size variant peaks are labeled from 1 to 11 (A) nrCE-SDS profiles of HIC prepeaks and main peak; (B) nrCE-SDS profiles of HIC post peaks.




# Table 1. nrCE-SDS peak assignment based on HIC fractionation study and partial reduction study (for peak 10 assignment)

nrCE-SDS pk #	Fragment	Mass (Da)		HIC enrichment	Complementary fragment	CE-SDS pk # for complimentary Frag.
		Theo	Detect			
1	Hole HC 1-102	11,109	11,108	HIC pre-pk 2, 3, 4, 5, 6 & post-pk 2		11
	Hole HC 1-101	10,992	10,992	Post-pk 5, 6		
	Hole HC1-109	12,106	12,105	Pre-pk 4		
1'	Knob HC1-99	11,019	11,019	All HIC fractions		11
	Knob HC1-103	11,403	11,402	HIC pre-pk 4, 5, 6		
	Knob HC1-106	11,778	11,778	HIC pre-pk 4, 5		
	Knob HC1-107	11,943	11,942	HIC pre-pk 4, 5		
2	$\kappa$ LC2-218	23,971	23,969	HIC pre-pk 7, 6		10
3	$\kappa$ LC + Cys	24,304	24,304	All HIC fractions		10
3'	$\lambda$ LC + Cys	23,041	23,041	HIC pre-pk 5, 6		10
4	Fab 2 fragment ( $\lambda$ LC-knob HC1-141, 143, 145)	38,370 38,558 38,702	38,370 38,558 38,701	HIC pre-pk 4, 5, 3 & post-pk 2		9
5	Fab 1 (hole ½Ab)	48,738 48,499 48,256 48,371 48,353	48,737 48,499 48,256 48,371 48,352	HIC pre-pk 7, 6		8'
6	Fab 2 (knob ½Ab)	47,875 47,208 47,637	47,873 47,206 47,639	HIC pre-pk 4, 5 & Post-pk 2		8
7						


7		97,908 97,891(Su)	97,906 97,890	HIC pre-peak 5 HIC pre-peak 4	NA (only impacted by cell culture condition; no complementary)	NA
8		101,903 102,207 101,537	101,905 102,208 101,537	HIC pre-pk 6, 3 & post-pk 2		6
8'		101,042 100,675	101,040 100,673	HIC pre-pk 2, 3, 4 & post-pk 2		5
9		111,041 110,853 110,709	ND (by LCMS)	HIC pre-pk 5 & post-pk 2		4
10		125,209	125,212	Enriched by partial reduction		3
		125,209	ND	ND		2
		126,472	126,477	Enriched by partial reduction		3'
		138,302	ND	HIC pre-pk 2, 3, 4, 5, 6 & post-pk 2		1
		138,419	ND (by LCMS)	post-pk 5, 6		1
		137,305	Pre-pk 4	Hole HC 1-109		1




**Figure 3.** CE-SDS profiles of bsAb-A non-stressed control and 40°C stressed Lot A at 1, 2 and 3 mon.




**Figure 4.** RP-LC UV profiles of denatured and reduced bsAb-A at 40°C 3 month (A), zoom-in of RP-LC UV profiles of denatured and reduced bsAb-A at 40°C 3 mon. (B); and deconvoluted spectra of CH2 and CH1 clipped reduced fragments (C to G). Red: Lot A; Blue: Lot B; Green: Lot C.




**Figure 5.** Tandem mass (MS/MS) spectra of peptides (L)TVLHQDWLNGK resulting from CH2 clipping at L306 (top) and (L)HQDWLNGK resulting from CH2 clipping at L309.




**Figure 6.** Deconvoluted mass spectra of Fc in bsAb-A 40°C 3 mon heat-stressed Lot A, Lot B and Lot C and unstressed control (top), and deconvoluted mass spectra of deglycosylated Fc in bsAb-A 40°C 3 mon heat-stressed Lot A, Lot B and Lot C and unstressed Control (bottom).






**Figure 7.** Deconvoluted mass spectra of Oxi-Fc and Fc in bsAb-A 40°C 3 mon heat-stressed Lot A (top), and RP-LC UV profile of bsAb-A subunits of heat-stressed Lot A at 40°C 3mon (bottom).




**Figure 8.** Deconvoluted mass spectra of Fab 1 and Fab 2 in bsAb-A 40°C 3 mon heat-stressed Lot A, Lot B and Lot C and unstressed Control. Top: Knob ½ Ab Fab; bottom: Hole ½ Ab Fab



**Figure 9.** nrCE-SDS and reduced RP-LC UV overlay of SEC fractions from 40C 1mon heat-stressed bsAb-A and relative amount of the CH<sub>2</sub> clippings at L306, L309 or D270 in SEC fractions. A: nrCE-SDS overlay; B: Reduced RP-LC UV overlay; C: Relative amount of the CH<sub>2</sub> clippings at L306, L309 or D270 in SEC fractions.



SEC Fractions	Protein loading ratio in RP-LC
Back shoulder	3.1
Monomer	3.7
Front shoulder	1.0
Aggregate	1.3
Fragment	0.8







**Table 2. Sequences in the vicinity of CH2 cleavage sites L306 and L309**

EU #	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317
IgG1	R	V	V	S	V	L	T	V	L	H	Q	D	W	L	N	G	K
IgG2	R	V	V	S	V	L	T	V	V	H	Q	D	W	L	N	G	K
IgG4	R	V	V	S	V	L	T	V	L	H	Q	D	W	L	N	G	K



**Figure 10.** Overlays of nrCE-SDS (A), rCE-SDS (B) and reduced RP-LCUV (C) and zoom-in overlay of reduced RP-LC UV (D) of 40°C 1Mon bsAb-A Lot A incubated with protease inhibitors and without protease inhibitors.



# Discussion

- Shoulder peak is related to protease activity in mAbs and bsAbs, and can be separated from the previously reported IgG missing HC N-terminal 100 amino acids
- C<sub>H</sub>2 clipping can be resolved in non-reduced CE-SDS profiles as a shoulder peak on the intact IgG
- The C<sub>H</sub>2 domain of IgGs is the most cleaved region and understanding these cleavages could help us better understand cleavages in other subclasses
- Identification of these clipping sites can lead to improve manufacturing and cell culture practices



# Acknowledgements

- Mingyan Cao
- Yang Jiao
- Samuel Korman
- Jiao Ma
- Alan Hunter
- Greg Kilby
- Xiaoyu Chen



# Questions



### **Confidentiality Notice**

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, [www.astrazeneca.com](http://www.astrazeneca.com)

